Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who benefited from the FDA news speculation "bubble"
Agreed-If-product-had-demand-EU-sales-would-be-showing-on-bottom-line
A year ago there were multiple PR mailings that suggested new channels being brought online would bring this to profitability
Now we are on the merry go round about FDA soon, very soon, again.
Do not be persuaded by the promise of returns, look at the price per share history and trade on speculation inflections, otherwise do not invest anything that is not similar to buying a weekly lottery ticket. In fact you might have higher statistical probability buying lottery tickets.
All indications from SEC violations is this is a family based TOXIC stock selling business model
Patience-is-a-virtue-in-due-time this TOXIC Stock selling business model will be shut down.
However, highly speculative that friends of family have learned well and will be able to reconstitute in another form/shape/fashion.....
Same game just names will be changed.
Amazing-denial-that-exists-Biel-has-been-found-guilty
The TOXIC dilution business model will need to be handed over to arms length family and friends.
QUELL-->Another-OTC-Patented-Product-Competing-for-same-TAM
--> Quell is a TENS device with a difference.
www.quellrelief.com/wp-content/uploads/2016/06/quell-consumer-brochure.pdf
www.quellrelief.com/how-quell-works/
BIEL's inability to execute within normally acceptable business and government regulations is what has lead to its demise
So we have "smart-relief" with an incredible spoke-person and now another well marketed "Quell" product that has ad-space on CNN for example......
Lights-out "soon"
FYI The average cost of a primetime ad on CNN typically runs a couple of grand, somewhere between $4,000 and $6,000, according to ad buyers
Not-according-to-Stanford-study
RE: ...most companies spend well over $100m....
Costs related to winning 510(k) clearance for a medical device that were directly related to satisfying Food & Drug Administration rules average $24 million, according to a Stanford University report
--> https://lmgtfy.com/?q=cost+for+fda+device+clearance
Compare the documents, Biel legal submission reads at an unprofessional level, while SEC "Division" reads at professional level.
Biel --> https://www.sec.gov/litigation/apdocuments/3-17104-event-115.pdf
SEC --> https://www.sec.gov/litigation/apdocuments/3-17104-event-116.pdf
$33M-significant-percentage-ill-gotten-gains
Division seeks $4,246,266 plus interest.....
Division seeks $397,196 plus interest.....
See page 36-40 & 46
https://www.sec.gov/litigation/apdocuments/3-17104-event-116.pdf
It does not take $33M to accomplish what BIEL has delivered over the 10+ years. Where did the ~$23M go?
If one speculates $250k to $500k per family member per year over 10+ years ...... one can start to arrive at a reasonable explanation for where the $33M went.
$33M-$5M-Disgorgement-->$28M-at-the-Whelans-family-discrecion
Division seeks $4,246,266 plus interest.....
Division seeks $397,196 plus interest.....
See page 36-40 & 46
https://www.sec.gov/litigation/apdocuments/3-17104-event-116.pdf
It does not take $33M to accomplish what BIEL has delivered over the 10+ years. Where did the ~$23M go?
If one speculates $250k to $500k per family member per year over 10+ years ...... one can start to arrive at a reasonable explanation for where the $33M went.
Agreed ==> Investors should be livid that BIEL wasted all of that money -> $33M
Simply-stated: the-evidence-warrants-maximum-penalties
https://www.sec.gov/litigation/apdocuments/3-17104-event-116.pdf
DOH!-"BIEL"-has-raised-$33-million-over-the-lifetime-of-the-company
https://www.sec.gov/litigation/apdocuments/3-17104-event-116.pdf
0.0002ASK-is-feasible-average-down-at-this-0.0004ASK-level-risks-50%-loss
PR-Model-->Agreed-paid-for-mocked-interview
Breathtaking-->15BAS-13BOS-0.0004PPS-after-over-10-years!
Not-an-opinion-company-statements-in-financial-reporting-documents
www.bielcorp.com/biel/wp-content/uploads/2016/09/showFinancialReportById-10.pdf
substantial-doubt-Company-ability-to-continue
NOTE 3 – GOING CONCERN
The Company has incurred substantial losses from operations. The Company sustained a net loss of $865,258 for
the six months ended June 30, 2016, and a total net loss since inception of $28,412,749. The Company is currently
seeking financing to provide the needed funds for operations. However, the Company can provide no assurance
that it will be able to obtain the financing it needs to continue its efforts for market acceptance, U.S. FDA approval
and to maintain operations, and thus there is substantial doubt of the Company’s ability to continue as a going
concern.
www.bielcorp.com/biel/wp-content/uploads/2016/09/showFinancialReportById-10.pdf
UK-Braun-never-had-luster-did-facilitate-PR-speculation-TOXIC-Dilution stock selling business model
Wait-for-the-"ASK"-0.0003s
Share-the-truth-help-others-avoid-the-same
Possibly-not-in-this-TOXIC-Stock-selling-business-model-though
Bias-and-optimism-are-not-going-to-change-the-facts
FDA while showing cordial/professional..... the facts are the company has been unable in 10+ years to follow proper process and satisfy necessary requirements.
Formally known as adhering to the 7-P's
--> www.facebook.com/The-Seven-Ps-Proper-Prior-Planning-Prevents-Piss-Poor-Performance-279919480824/
SEC-and-FDA-and-Investors-have-stark-disagreements
SEC disagrees with company leadership business ethics
FDA disagrees with product efficacy
Investors disagree based on PPS trending below 0.0005 on glide path to 0.0000
More-crickets-if-you-ask-those-same-how-many-made-money-at-0.001
Inconceivable how committed some are to loosing money by buying into this TOXIC Stock selling business model
PPS-near-0.0000000-are-we-not-investors? Key/Bottom-Line indices are being ignored or not sure what the heck is the motivation cant be to lose money?
JGD-Is-it-not-clear-by-now-that-biel-has-failed in various facets that matter to investors that would like to see a return on capital and any and all efforts to misconstrue the obvious are futile
Part-of-the-PR-strategy-was-to-grab-the-name-BioElectronics
Without a doubt, this is example of few key decisions that have contributed to the fact BIEL has persevered this many years.
However this "name association" actually only facilitates TOXIC Stock Selling
Soon ;)
All-the-bullets-yet-most-important-ignored PPS down HUGE!
Says-the-investor-who-purchased-at-0.001
BIEL will be trading at 0.004 "soon"
Tsunami of buying will hit at those levels "soon"
Hint->Buy-Shares-at-0.004-and-below
Ignores-the-time-variant-->Dilution-becomes-TOXIC-selling when done far too long
Agreed any concept, in this case Dilution is viable, the problem, like with anything, the time at which this is acceptable is not unlimited and Biel leadership and exceeded what is reasonable period of time to "get it done."
Dilution becomes TOXIC selling when the time variant is exceeded.
The family funding model can also be acceptable for a reasonable period of time, again Biel leadership and far exceeded what is an reasonable period of time.
That's why we are at 15B AS and likely much higher for those share's un-accounted for.
Yes-indeed-the-TOXIC-stock-selling-buiness-model-is-alive-and-well
Thanks to a very well executed marketing campaign, pink sheet funding expertise and uninformed investors.
SEC has begun executing a plan to reduce the violations in the current business model.
FDA to date has been unable to coerce the company leadership into providing the necessary scientific data to clear the product for OTC
Assumption-being-discussion-reflects-prior-to-cutoff-date
Does not speculate on the fact after a certain date the whole discussion is mute.
Too-vague-to-be-actionable-as-usual
That's the business model strategy, be optimistic enough to help stimulate TOXIC sale of stocks, yet vague enough to not be accountable to anything definitive.
IE: We see no reason to not have clearance by end of year 2015
Which should not be confused with we will have clearance by end of the year 2015
Read the post closely and pull key words, these all are specifically intended to remove any "accountability"
"Hopefully"
"intended"
"soon"
"close"
"would"
"Concerning FDA clearance for Actipatch from my conversation with Andy. Hopefully this clarifies some of the concerns regarding their concerns; He was very easy to contact and pleasant to talk to. I asked him about the FDA, Ibex, dilution and sales. He stated that the FDA requested more clinical data, which BIEL provided this week. He stated that the reason they needed further data was because musculoskeletal use is a much broader application than what was applied for and it is intended to expand the indication. The 510(k) pathway to clearance is alive and well. There will be a press release from BIEL giving us an update on some of these matters soon. There is more info to be presented regarding Ibex. He couldn't say much more about it. He also stated they are close to not having to dilute any more. Sales are expected to increase with the new store additions. He said with FDA clearance in the USA it would take four to six weeks to have product to supply Walgreens and any other stores that would stock ActiPatch. He also stated there are continuing studies for bladder related issues." Soon
Right-what-clients-request-to-WIN-is-not-always-in-thier-best-interest
Lawyers-highest-priorities-is-billable-hours not necessarily the customers best interest, especially if customer is adamant and too some degree going against recommendations.
Have-purchased/used-product.....
However, that does not interfere with "Investment Rationalization"
Problem is company leadership not the product.
Might be a fantastic idea/product, lack of execution has failed all investors to date.
"zero competition"-is-false-Smart-Relief-has-identical-TAM
Smart-Relief is targeting the exact same population, also known as TAM
If you really want to understand Biel product opportunities study the revenue's associated to Smart-Relief
The reality is Biel missed the boat years ago and as well will never be able to effectively compete against the Brand recognition, sponsorship and market lead that Smart-Relief already has established.
All the hype about tsunami's of revenue and or sales is just that hype to sell into the TOXIC Stock selling business model that Biel has effectively established and continues to leverage quite well. For BIEL to not succumb to multiple different FDA and SEC failures is, well, astonishing.
Yeah-there-is-some-paint-the-tape-at-the-end-of-the-day-stuff-going-on as well they are not selling at the average ASK, likely selling below the BID.....
SWAG-1B==>PPS-down-50%-thus-dilution-velocity-more-than-doubles
Given nearly 50% on average lower stock price in addition to expected significant legal expenses suggest the estimate of
650M shares is well below what will be realized.
SWAG at about 1B additional shares floated to cover historical operating expenses and the additional legal expenses with reduced valued shares.